Trial Profile
Phase II multicenter single-arm study evaluating the safety and efficacy of everolimus as a first-line treatment in newly-diagnosed patients with advanced GI neuroendocrine tumors.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 30 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 30 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018.
- 28 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.